Heideman D A M, Snijders P J F, Berkhof J, Verheijen R H M, Helmerhorst T J M, Meijer C J L M
Department of Pathology, VU Medical Centre, Amsterdam, the Netherlands.
BJOG. 2008 Jul;115(8):938-46. doi: 10.1111/j.1471-0528.2008.01779.x.
A novel approach for primary prevention of cervical cancer has become available by the discovery of efficient prophylactic human papillomavirus (HPV) vaccines based on virus-like particles. This review elaborates on the progress in the field of prophylactic HPV vaccination achieved in the past decade, provides indications for prophylactic HPV vaccination, and discusses the impact on public health and the current secondary prevention system. In summary, with current vaccines, effective prevention and control of cervical cancer within the next decades requires an integrated vaccination-screening approach, including routine prophylactic vaccination to young women and adapted cervical screening for older women (> or =30 years).
基于病毒样颗粒的高效预防性人乳头瘤病毒(HPV)疫苗的发现,为宫颈癌的一级预防提供了一种新方法。本综述阐述了过去十年在预防性HPV疫苗接种领域取得的进展,给出了预防性HPV疫苗接种的适应证,并讨论了其对公共卫生和当前二级预防体系的影响。总之,使用目前的疫苗,要在未来几十年内有效预防和控制宫颈癌,需要采取疫苗接种与筛查相结合的方法,包括对年轻女性进行常规预防性疫苗接种,以及对老年女性(≥30岁)进行适应性宫颈癌筛查。